skip to content

Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology Corporation

January 25, 2017

TORRANCE, Calif. – January 25, 2017 - Emmaus announced today that its Chairman and Chief Executive Officer, Yutaka Niihara, MD, MPH, has joined the Board of Directors of Generex Biotechnology Corporation (“Generex”, OTCPink:GNBT) as Executive Chairman. This follows the prior announcement that Emmaus entered into a Letter of Intent on a collaborative agreement with Generex. Emmaus filed a Form 8-K Current Report in respect of the agreement with the U.S. Securities and Exchange Commission on January 20, 2017. Emmaus is also an SEC registrant; its filings, including audited financial information, are publicly available at

Generex is working toward rebuilding its company with a plan toward up-listing to a major stock exchange. Emmaus is working toward achieving approval and commercialization of its treatment for sickle cell disease.

Joseph Moscato, Generex President & Chief Executive Officer, stated: “We welcome Dr. Niihara and look forward to his contributions to our joint efforts to advance both Generex and Emmaus technologies.

“This is another symbol of how Emmaus and Generex will collaborate on the synergistic growth of Generex and Emmaus,” commented Dr. Yutaka Niihara, MD, MPH, Emmaus’ Chief Executive Officer. “I look forward to working closely with the team at Generex.”

About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit

Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

For more information, contact:

Jim Heins
Senior Vice President
ICR Healthcare

Charles Butler
Senior Vice President
ICR Healthcare